LSL Pharma Group

LSL Pharma Group EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of LSL Pharma Group (LSL.V) as of Nov 1, 2026 is 28,000.00 CAD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 589,000.00 CAD — a change of -95.25% (lower).

EBITDA

28,000.00CAD

YoY

-95.25%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of LSL Pharma Group is 2025 28,000.00 CAD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of LSL Pharma Group was 2024 589,000.00 CAD. It decreases by -95.25% lower compared to the previous year.

The LSL Pharma Group EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2020
809,271.00 CAD
Jan 1, 2021
-65,267.00 CAD
Jan 1, 2022
-6.68 M CAD
Jan 1, 2023
-6.58 M CAD
Jan 1, 2024
589,000.00 CAD
Jan 1, 2025
28,000.00 CAD
The LSL Pharma Group EBITDA history
YEAREBITDAYoY
28,000.00CAD-95.25%
589,000.00CAD-108.95%
-6.58 MCAD-1.44%
-6.68 MCAD+10,128.75%
-65,267.00CAD-108.06%
809,271.00CAD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

LSL Pharma Group Stock analysis

What does LSL Pharma Group do? LSL Pharma Group, Inc. generates revenue through the development, manufacturing, and distribution of natural health products and dietary supplements in solid dosage forms, as well as sterile ophthalmic pharmaceutical products. The company operates as a pharmaceutical entity specializing in these specific therapeutic and wellness categories to meet market demand. The firm utilizes its subsidiaries, including Steri-Med Pharma Inc., LSL Laboratory Inc., and Groupe Immobilier LSL inc., to support its core operations. These entities facilitate the company's ability to produce and distribute its specialized pharmaceutical and supplement offerings effectively within its operational framework. LSL Pharma Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about LSL Pharma Group stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of LSL Pharma Group is 28,000.00 CAD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of LSL Pharma Group changed from 589,000.00 CAD to 28,000.00 CAD, representing a -95.25% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) LSL Pharma Group since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s CAD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s LSL Pharma Group historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — LSL Pharma Group

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — LSL Pharma Group